Liver-Targeted Therapies Rescue Lysine Disorders in Mice

American Association for the Advancement of Science (AAAS)

In a new pair of studies, researchers present therapeutics that target the liver to treat severe inherited metabolic disorders that prevent the full breakdown of the amino acid lysine. Taken together, their experiments showcase the clinical potential of strategies such as antisense oligonucleotides (ASOs) and silencing RNAs to treat these metabolic diseases, which currently have no cure. Lysine facilitates the synthesis of proteins and various metabolic processes, and is usually broken down in the liver and kidneys. However, some mutations prevent other enzymes from properly breaking down lysine, leading to the toxic buildup of intermediate lysine byproducts and to disorders such as ALDH7A1 deficiency and glutaric aciduria type I. Patients with these diseases experience severe and debilitating symptoms ranging from early-onset seizures to movement issues. Clinicians currently rely on dietary restrictions and supplements to manage symptoms, but many patients still end up with lifelong neurological complications.

In the first paper, Reddy Sreekanth Vootukuri and colleagues set out to address the need for therapies that can suppress toxic metabolites more effectively. They turned to ASOs, which target RNAs to modify or suppress gene expression. The researchers employed ASOs that silence the activity of the gene AASS, which has previously been identified as a target in lysine metabolic disorders. By conjugating the ASO to a molecule called N­-acetylgalactosamine, Vootukuri et al. found that they could specifically target liver cells and knock down AASS expression in both wild-type mice and a mouse model of ALDH7A1 deficiency. The ASOs reduced the accumulation of toxic lysine byproducts in the rodents and in cells derived from patients with either ALDH7A1 deficiency or glutaric aciduria type I. Meanwhile, Yunhan Ma and colleagues tested a similar liver-targeted approach that uses AASS-silencing RNAs conjugated to N-­acetylgalactosamine. The therapy mitigated brain damage and curtailed levels of toxic metabolites in the organs when given to a newborn mouse model of glutaric aciduria type I. "Integration of RNA-based therapies with newborn screening programs may be critical if prevention of cerebral metabolite accumulation is required to improve neurological outcomes," Vootukuri et al. note when discussing clinical implementation.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.